JP2020500167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500167A5 JP2020500167A5 JP2019521703A JP2019521703A JP2020500167A5 JP 2020500167 A5 JP2020500167 A5 JP 2020500167A5 JP 2019521703 A JP2019521703 A JP 2019521703A JP 2019521703 A JP2019521703 A JP 2019521703A JP 2020500167 A5 JP2020500167 A5 JP 2020500167A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- peptide
- group
- alkenyl
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 125000000539 amino acid group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022155872A JP2022191303A (ja) | 2016-10-26 | 2022-09-29 | Ｆｏｘｐ３結合ペプチド及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16195686.7 | 2016-10-26 | ||
| EP16195686 | 2016-10-26 | ||
| PCT/EP2017/076690 WO2018077716A1 (en) | 2016-10-26 | 2017-10-19 | Foxp3-binding peptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155872A Division JP2022191303A (ja) | 2016-10-26 | 2022-09-29 | Ｆｏｘｐ３結合ペプチド及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500167A JP2020500167A (ja) | 2020-01-09 |
| JP2020500167A5 true JP2020500167A5 (https=) | 2020-11-26 |
| JP7212942B2 JP7212942B2 (ja) | 2023-01-26 |
Family
ID=57209245
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521703A Active JP7212942B2 (ja) | 2016-10-26 | 2017-10-19 | Ｆｏｘｐ３結合ペプチド及びその使用 |
| JP2022155872A Pending JP2022191303A (ja) | 2016-10-26 | 2022-09-29 | Ｆｏｘｐ３結合ペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155872A Pending JP2022191303A (ja) | 2016-10-26 | 2022-09-29 | Ｆｏｘｐ３結合ペプチド及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10654896B2 (https=) |
| EP (1) | EP3532482A1 (https=) |
| JP (2) | JP7212942B2 (https=) |
| AU (1) | AU2017349979B2 (https=) |
| ES (1) | ES2665543B1 (https=) |
| WO (1) | WO2018077716A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2665543B1 (es) * | 2016-10-26 | 2019-02-12 | Fundacion Para La Investig Medica Aplicada | Péptidos de unión a FOXP3 y usos de los mismos |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| EP1105479B1 (en) | 1998-08-11 | 2011-01-12 | Darwin Discovery Limited | Identification of the gene causing the mouse scurfy phenotype and its human ortholog |
| WO2009020865A1 (en) | 2007-08-03 | 2009-02-12 | The Board Of Regents Of The University Of Nebraska | Surface-modified nanoparticles for intracellular delivery of therapeutic agents and composition for making same |
| ES2328776B1 (es) * | 2007-11-19 | 2010-07-06 | Proyecto De Biomedicina Cima S.L. | Peptidos con capacidad para unirse a escurfina y aplicaciones. |
| CA2939711C (en) * | 2014-02-21 | 2020-09-29 | Cellectis | Method for in situ inhibition of regulatory t cells |
| ES2665543B1 (es) * | 2016-10-26 | 2019-02-12 | Fundacion Para La Investig Medica Aplicada | Péptidos de unión a FOXP3 y usos de los mismos |
-
2017
- 2017-03-29 ES ES201700439A patent/ES2665543B1/es active Active
- 2017-10-19 AU AU2017349979A patent/AU2017349979B2/en active Active
- 2017-10-19 EP EP17794248.9A patent/EP3532482A1/en not_active Withdrawn
- 2017-10-19 US US16/343,394 patent/US10654896B2/en active Active
- 2017-10-19 WO PCT/EP2017/076690 patent/WO2018077716A1/en not_active Ceased
- 2017-10-19 JP JP2019521703A patent/JP7212942B2/ja active Active
-
2020
- 2020-04-20 US US16/853,397 patent/US11560407B2/en active Active
-
2022
- 2022-09-29 JP JP2022155872A patent/JP2022191303A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2449615T3 (es) | Péptidos y su uso | |
| JP2012500001A5 (https=) | ||
| JP2016515620A5 (https=) | ||
| JP5954736B2 (ja) | 難治性炎症性腸疾患の予防又は治療方法 | |
| EP3533461A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
| JP2022514255A5 (https=) | ||
| JP2016501204A5 (https=) | ||
| JPS63264498A (ja) | 黄体形成ホルモン放出ホルモンのノナペプチド及びデカペプチド誘導体 | |
| JP2012067099A5 (https=) | ||
| JPWO2019107530A5 (https=) | ||
| JP2017523184A5 (https=) | ||
| JP2009537624A5 (https=) | ||
| CN115957296A (zh) | 药物组合物 | |
| CN103304631A (zh) | 具有抗肿瘤活性的九肽 | |
| RU2016110153A (ru) | Новые пептиды и их аналоги для применения при лечении мукозита полости рта | |
| CN101273059A (zh) | 治疗活性的α-MSH类似物 | |
| US20170319645A1 (en) | Compositions and methods for treating acute radiation syndrome | |
| JP2024516613A5 (https=) | ||
| WO2017079430A1 (en) | Peptides and methods of treating endometriosis using the same | |
| ITMI981094A1 (it) | Uso di proteina hmg-i per la preparazione di medicamenti ad attivita' citotossica | |
| WO2020230780A1 (ja) | Ｒａｓ阻害ペプチド | |
| JP2018521977A5 (https=) | ||
| JP2018519254A5 (https=) | ||
| ES2882827T3 (es) | Péptido inductor de inmunidad derivado de HSP70 | |
| WO2005030238A1 (fr) | Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique |